Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application:

Listing of claims:

Claim 1. (Currently amended) A compound of Formula I:



(I)

in which

n is selected from 1, 2 and 3;

Z is selected from C and S(O); each

Y is independently selected from $-CR_4=$;

wherein R_4 is selected from hydrogen, cyano, hydroxyl, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl and halo-substituted-C_{1-6}alkoxy;

R_1 is selected from halo, cyano, hydroxyl, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy and $-C(O)OR_4$; wherein R_4 is selected from hydrogen, cyano, hydroxyl, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl and halo-substituted-C_{1-6}alkoxy;

R_2 is selected from C_{6-10}aryl, and C_{3-12}cycloalkyl; wherein any aryl or cycloalkyl of R_2 is optionally substituted with 1 to 5 radicals independently selected from halo, hydroxy, cyano, nitro, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, $-C(O)NR_5R_5$, $-OR_5$, $-OC(O)R_5$, $-NR_5R_6$, $-C(O)R_5$ and $-NR_5C(O)R_5$;

wherein:

R_5 and R_6 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, C_{6-}

$_{10}$aryl-C_{0-4}alkyl, and C_{3-12}cycloalkyl-C_{0-4}alkyl; wherein any aryl or cycloalkyl of R_5 is optionally substituted with 1 to 4 radicals independently selected from halo, hydroxy, cyano, nitro, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl and halo-substituted-C_{1-6}alkoxy;

R_3 is selected from C_{6-10}aryl and C_{3-12}cycloalkyl; wherein any aryl or cycloalkyl of R_3 is substituted with 1 to 5 radicals independently selected from halo, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, -OXR_7, -$OXC(O)NR_7R_8$, -$OXC(O)NR_7XC(O)OR_8$, -$OXC(O)NR_7XOR_8$, -$OXC(O)NR_7XNR_7R_8$, -$OXC(O)NR_7XS(O)_{0-2}R_8$, -$OXC(O)NR_7XNR_7C(O)R_8$, -$OXC(O)NR_7XC(O)XC(O)OR_8$, -$OXC(O)NR_7R_9$, -$OXC(O)OR_7$, -$OXOR_7$, -OXR_9, -XR_9, -$OXC(O)R_9$, -$OXS(O)_{0-2}R_9$ and -$OXC(O)NR_7CR_7[C(O)R_8]_2$;

wherein:

X is a selected from a bond and C_{1-6}alkylene wherein any methylene of X can optionally be replaced with a divalent radical selected from C(O), NR_7, $S(O)_2$ and O;

R_7 and R_8 are independently selected from hydrogen, cyano, C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl, C_{2-6}alkenyl and C_{3-12}cycloalkyl-C_{0-4}alkyl;

R_9 is selected from C_{6-10}aryl-C_{0-4}alkyl and C_{3-12}cycloalkyl-C_{0-4}alkyl; wherein any alkyl of R_9 can have a hydrogen replaced with -$C(O)OR_{10}$; and any aryl or cycloalkyl of R_9 is optionally substituted with 1 to 4 radicals independently selected from halo, C_{1-6}alkyl, C_{3-12}cycloalkyl, halo-substituted-C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkoxy, -$XC(O)OR_{10}$, -$XC(O)R_{10}$, -$XC(O)NR_{10}R_{10}$, -$XS(O)_{0-2}NR_{10}R_{10}$ and -$XS(O)_{0-2}R_{10}$;

wherein:

R_{10} is independently selected from hydrogen and C_{1-6}alkyl;

~~and thepharmaceutically acceptable salts, hydrates, solvates and isomers thereof~~

or a pharmaceutically acceptable salt or isomer thereof.

Claim 2. (Previously presented) The compound of claim 1 of Formula Ia:



(Ia)

in which

n is selected from 1, 2 and 3;

Y is selected from –CH=;

R_1 is selected from halo, C_{1-6}alkyl, and –C(O)OR_4; wherein R_4 is selected from hydrogen and C_{1-6}alkyl;

R_2 is selected from C_{6-10}aryl and C_{3-12}cycloalkyl; wherein any aryl or cycloalkyl of R_2 is optionally substituted with 1 to 4 radicals independently selected from halo, hydroxy, C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl and –OC(O)R_5; wherein R_5 is selected from hydrogen and C_{1-6}alkyl; and

R_3 is selected from C_{6-10}aryl and C_{3-12}cycloalkyl; wherein any aryl or cycloalkyl of R_3 is substituted with 1 to 5 radicals independently selected from halo, hydroxyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, -OXR_7, -OXC(O)NR_7R_8, -OXC(O)NR_7XC(O)OR_8, -OXC(O)NR_7XOR_8, -OXC(O)NR_7XNR_7R_8, -OXC(O)NR_7X$S(O)_{0-2}R_8$, -OXC(O)NR_7XNR_7C(O)R_8, -OXC(O)NR_7XC(O)XC(O)OR_8, -OXC(O)NR_7R_9, -OXC(O)OR_7, -OXOR_7, -OXR_9, -XR_9, -OXC(O)R_9 and -OXC(O)$NR_7CR_7[C(O)R_8]_2$;

wherein

X is a selected from a bond and C_{1-6}alkylene;

R_7 and R_8 are independently selected from hydrogen, cyano, C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl, C_{2-6}alkenyl and C_{3-12}cycloalkyl-C_{0-4}alkyl;

R_9 is selected from C_{6-10}aryl-C_{0-4}alkyl and C_{3-12}cycloalkyl-C_{0-4}alkyl; wherein any alkyl of R_9 can have a hydrogen replaced with –C(O)OR_{10}; and any aryl or cycloalkyl of R_9 is optionally substituted

with 1 to 4 radicals independently selected from halo, C_{1-6}alkyl, C_{3-12}cycloalkyl, halo-substituted-C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkoxy, $-XC(O)OR_{10}$, $-XC(O)R_{10}$, $-CR_{10}(NR_{10}R_{10})=NOR_{10}$, $-XC(O)NR_{10}R_{10}$, $-XS(O)_{0-2}NR_{10}R_{10}$ and $-XS(O)_{0-2}R_{10}$;

wherein

R_{10} is independently selected from hydrogen and C_{1-6}alkyl.

Claim 3. (Previously presented) The compound of claim 2 in which

R_1 is selected from fluoro, chloro, methyl and $-C(O)OCH_3$; and

R_2 is selected from phenyl, cyclohexyl, cyclopentyl, and naphthyl; wherein any aryl or cycloalkyl of R_2 is optionally substituted with 1 to 4 radicals independently selected from fluoro, chloro, bromo, hydroxy, methyl, ethyl, propyl, t-butyl, amino, dimethyl-amino, methoxy, trifluoromethyl, trifluoromethoxy and $-OC(O)CH_3$.

Claim 4. (Previously presented) The compound of claim 3 in which R_3 is phenyl substituted with 1 to 5 radicals independently selected from fluoro, chloro, bromo, methoxy, hydroxyl, difluoromethoxy, $-OCH_2C(O)NH_2$, $-OCH_2C(O)OCH_3$, $-OCH_2C(O)NHCH_3$, $-OCH_2C(O)N(CH_3)_2$, $-R_9$, $-OR_9$, $-OCH_2R_9$, $-OCH_2C(O)R_9$, $-OCH_2C(O)NHR_9$, $-OCH_2C(O)N(CH_3)R_9$, $-OCH_2C(O)NHCH_2R_9$, $-OCH_2CN$, $-OCH_2C_2H_3$, $-OCH_2C_2H_4$, $-O(CH_2)_2OH$, $-OCH_2C(O)NH(CH_2)_2C(O)OC_2H_5$, $-OCH_2C(O)NH(CH_2)_2CH_2F$, $-OCH_2C(O)NHCH_2CH_2F$, $-OCH_2C(O)NH(CH_2)_2C(O)OH$, $-OCH_2C(O)NHCH(CH_2R_9)C(O)OC_2H_5$, $-OCH_2C(O)NHC(O)(CH_2)_2C(O)OCH_3$, $-OCH_2C(O)NH(CH_2)_2NHC(O)CH_3$, $-OCH_2C(O)NHCH_2C(O)C_2H_5$, $-OCH_2C(O)NH(CH_2)_2C(O)OC_4H_9$, $-OCH_2C(O)NHCH_2C(O)OC_2H_5$, $-OCH_2C(O)NHCH[C(O)OC_2H_5]_2$, $-S(O)_2CH_3$, $-OCH_2C(O)NHCH_2CF_3$, $-OCH_2C(O)NHCH_2C(O)(CH_2)_2C(O)OCH_3$, $-OCH_2C(O)N(CH_3)CH_2C(O)OCH_3$, $-OCH_2C(O)NH(CH_2)_3OC_2H_5$, $-OCH_2C(O)NH(CH_2)_3OCH(CH_3)_2$, $-OCH_2C(O)NH(CH_2)_2SCH_3$, $-OCH_2C(O)NHCH_2CH(CH_3)_2$, $-OCH_2C(O)NHCH(CH_3)CH_2OH$, $-OCH_2C(O)NHCH_2CH(CH_3)C_2H_5$, $-OCH_2C(O)NHCH(CH_3)C(O)OC_2H_5$, $-OCH_2C(O)NHCH_2CH(CH_3)_2$ and $-OCH_2C(O)(CH_2)_3OCH(CH_3)_2$;

wherein

R_9 is phenyl, cyclopropyl-methyl, phenethyl; wherein any alkyl of R_9 can have a hydrogen replaced with $–C(O)OC_2H_5$; wherein any aryl of R_9 is optionally substituted with 1 to 4 radicals independently selected from methyl, ethyl, cyclopropyl, methoxy, trifluoromethyl, $–OC(O)CH_3$, $-COOH$, $-S(O)_2NH_2$, $-CH(NH_2)=NOH$, $–C(O)OC_2H_5$, $-CH_2C(O)OH$, $-CH_2C(O)OC_2H_5$, $-CH_2C(O)OCH_3$, $-C(O)OCH_3$, $-C(O)NH_2$, $-C(O)NHCH_3$ and $–C(O)CH_3$.

Claim 5. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.

Claim 6. (Cancelled) ~~A method for treating a disease or disorder in an animal in which modulation of LXR activity can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1~~.

Claim 7. (Cancelled) ~~The method of claim 6 wherein the diseases or disorder are selected from cardiovascular disease, diabetes, neurodegenerative diseases and inflammation~~.

Claim 8. (Cancelled).

Claim 9. (Cancelled) ~~A method for treating a disease or disorder in an animal in which modulation of LXR activity can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1~~.

Claim 10. (Cancelled) ~~The method of claim 9 further comprising administering a therapeutically effective amount of a compound of Claim 1 in combination with another therapeutically relevant agent~~.

Claim 11. (Currently amended) The compound of claim1 selected from:

 ,  ,  ,  ,

 ,  ,  ,

 ,  ,  ,

 ,  ,  , 

,  ,  ,  ,  ,

 ,  ,  ,  ,

 ,  ,  ,  ,

 ,  ,  , 

,  ,  ,  ,  ,

 ,  ,  ,  ,






,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

and

.